On December 17, 2020 Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported that it will host a virtual Analyst and Investor event on Tuesday, January 5, 2021 from 10:00 a.m. to 12:00 p.m. ET (Press release, Mersana Therapeutics, DEC 17, 2020, View Source [SID1234575006]). The event will showcase the following agenda:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Debra L. Richardson, MD, Associate Professor and Section Chief, Division of Gynecologic Oncology at the OU Health Stephenson Cancer Center and the Sarah Cannon Research Institute, will review updated data from the ovarian cancer cohort of the Phase 1 expansion study evaluating XMT-1536, the Company’s first-in-class ADC candidate targeting NaPi2b.
Mersana’s management team will detail the Company’s plans for the registration-enabling study of XMT-1536 in platinum-resistant ovarian cancer and outline its objectives for longer-term life cycle management studies to evaluate the potential of XMT-1536 in platinum-sensitive ovarian cancer.
Mersana’s management team will disclose preclinical data supporting the development of the Company’s first-in-class B7-H4 DolaLock ADC development candidate.
Mersana’s management team will outline the Company’s anticipated 2021 goals and milestones for its clinical and early-stage ADC programs.
Webcast and Conference Call Details
A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at View Source Analyst and Investors may ask a question during the live Q&A by dialing (855) 940-5308 (toll-free domestic) or (929) 517-9745 (international) and providing the Conference ID 6265117.